| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 1.22B | — |
| Operating expense | — | — |
| Net income | 338.41M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, IX1.F returned -13.1% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -17.8% |
| 1 year | -13.1% |
| 5 years | -17.2% |
| 10 years | +377.6% |
| All-time high | €651.20 (Nov 2025) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in IX1.F would be worth today ›No. IDEXX Laboratories, Inc. has not paid a dividend in the past 12 months.
IDEXX Laboratories, Inc. is part of the Healthcare sector.
IDEXX Laboratories, Inc. has a market cap of 37.67B EUR, based on the latest quote.
IDEXX Laboratories, Inc. is expected to report earnings around Nov 2, 2026. That date is an estimate and has not been confirmed by the company.
